Literature DB >> 24297641

Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report.

J Bogaczewicz1, T Sobów, A Bogaczewicz, E Robak, P Bienkowski, A Sysa-Jedrzejowska, A Wozniacka.   

Abstract

Despite precise definitions and exclusions for 19 syndromes of neuropsychiatric systemic lupus erythematosus (NPSLE), under some circumstances it appears to be difficult to differentiate whether neuropsychiatric symptoms are caused by SLE or by other reasons such as primary mental disorders or substance-induced mood disorders, especially induced by glucocorticoids or antimalarials. We report the case of a male patient with SLE who presented with an exacerbation of bipolar disorder triggered by chloroquine. Firstly, when the patient was diagnosed with SLE, he underwent six months of therapy with chloroquine without any psychiatric symptoms. Later, the SLE returned and the patient was prescribed chloroquine again, without any mental illness. When the third exacerbation of SLE occurred, it coincided with a severe depressive episode with psychotic features that became aggravated for the first time after the administration of chloroquine. The chloroquine was subsequently replaced with hydroxychloroquine for the next six months without any behavioral problems, following which, the SLE and mood disorder were in remission. Later, a bipolar disorder relapse occurred, manifested by a manic episode, and in the following three months, despite psychiatric treatment, a manic episode with psychotic features developed four days after chloroquine was prescribed for arthritis. It was the second time that the mood disorder was exacerbated by chloroquine. Since that time, chloroquine has been withdrawn. Currently the patient is undergoing treatment with hydroxychloroquine and psychiatric drugs with good response. Our case points out that although chloroquine-induced psychosis is rare, patients presenting with behavioral changes need physicians' attention in order to diagnose early and efficiently treat encountered mood disorders.

Entities:  

Keywords:  Systemic lupus erythematosus; chloroquine; neuropsychiatric lupus

Mesh:

Substances:

Year:  2013        PMID: 24297641     DOI: 10.1177/0961203313513818

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

Review 1.  Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article.

Authors:  Annamaria Mascolo; Pasquale Maria Berrino; Pietro Gareri; Alberto Castagna; Annalisa Capuano; Ciro Manzo; Liberato Berrino
Journal:  Inflammopharmacology       Date:  2018-06-09       Impact factor: 4.473

Review 2.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

Review 3.  Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Authors:  Remington L Nevin; Ashley M Croft
Journal:  Malar J       Date:  2016-06-22       Impact factor: 2.979

4.  Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy.

Authors:  Nicole M Maxwell; Remington L Nevin; Stephen Stahl; Jerald Block; Sarah Shugarts; Alan H B Wu; Stephen Dominy; Miguel Alonso Solano-Blanco; Sharon Kappelman-Culver; Christopher Lee-Messer; Jose Maldonado; Andrew J Maxwell
Journal:  Clin Case Rep       Date:  2015-04-09

5.  Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis.

Authors:  Mary A Bitta; Symon M Kariuki; Clifford Mwita; Samson Gwer; Leah Mwai; Charles R J C Newton
Journal:  Wellcome Open Res       Date:  2017-06-02

6.  Course of Neuropsychiatric Symptoms during Flares of Systemic Lupus Erythematosus (SLE).

Authors:  Gareth Garrett; Nicola Ambrose; Zaib Davids; Dorothea Bindman
Journal:  Case Rep Psychiatry       Date:  2017-02-23

Review 7.  Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19.

Authors:  George G Zhanel; Michael A Zhanel; Kevin F Boreskie; Joseph P Lynch; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-09-15       Impact factor: 2.471

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.